---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-031713"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-04-03T23:59:59+00:00"
generated_at: "2026-05-23T22:41:34.885081+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics enters ATM equity distribution agreement for up to $8.135M

## Summary
- Entered Equity Distribution Agreement with Canaccord Genuity LLC on April 3, 2025.
- May sell up to $8,135,000 of common stock via at-the-market offerings under existing shelf registration.
- Canaccord receives up to 3.0% commission on gross proceeds; Company reimburses certain expenses.
- Shares sold through Nasdaq or other trading market at prevailing prices with no minimum price.

## SEC filing metadata
- accession: 0001104659-25-031713
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925031713/0001104659-25-031713-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925031713/tm2511361d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-031713
- JSON: https://secwatch.observer/filing/0001104659-25-031713.json
- Plain text: https://secwatch.observer/filing/0001104659-25-031713.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.